Caila B Vaughn, Katelyn S Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman
{"title":"患者报告的结果是肌内干扰素β-1a使用者疾病失能的最强预测因子。","authors":"Caila B Vaughn, Katelyn S Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman","doi":"10.2217/nmt-2022-0008","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). <b>Materials:</b> 646 pwMS treated with interferon-β-1a (IFN-β-1a) were retrospectively included from the New York State Multiple Sclerosis Consortium. Clinical and PRO data at enrollment and 3 year follow-up were collected. PwMS with stable disease and disability worsening were matched (1:1) based on age, Expanded Disability Status Scale (EDSS) scores and disease duration. Disability worsening was determined based on trial criteria. <b>Results:</b> PwMS with future EDSS worsening had higher baseline and follow-up timed-25-foot walk (6.6 vs 5.5 s; 9.1 vs 5.5 s; p < 0.001) when compared with stable pwMS. Worsening pwMS reported higher baseline difficulties in getting up (odds ratio [OR] = 2.4; p = 0.009), climbing stairs (OR = 1.6; p = 0.024) and standing (OR = 2.2; p < 0.001). Worsening pwMS reported greater lower limb limitations (OR = 2.3; p = 0.004) and fatigue (OR = 1.8; p = 0.002). <b>Conclusion:</b> Higher fatigue and lower limb functional limitations are significant predictors of future disability worsening in pwMS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"151-159"},"PeriodicalIF":2.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users.\",\"authors\":\"Caila B Vaughn, Katelyn S Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman\",\"doi\":\"10.2217/nmt-2022-0008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Introduction:</b> Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). <b>Materials:</b> 646 pwMS treated with interferon-β-1a (IFN-β-1a) were retrospectively included from the New York State Multiple Sclerosis Consortium. Clinical and PRO data at enrollment and 3 year follow-up were collected. PwMS with stable disease and disability worsening were matched (1:1) based on age, Expanded Disability Status Scale (EDSS) scores and disease duration. Disability worsening was determined based on trial criteria. <b>Results:</b> PwMS with future EDSS worsening had higher baseline and follow-up timed-25-foot walk (6.6 vs 5.5 s; 9.1 vs 5.5 s; p < 0.001) when compared with stable pwMS. Worsening pwMS reported higher baseline difficulties in getting up (odds ratio [OR] = 2.4; p = 0.009), climbing stairs (OR = 1.6; p = 0.024) and standing (OR = 2.2; p < 0.001). Worsening pwMS reported greater lower limb limitations (OR = 2.3; p = 0.004) and fatigue (OR = 1.8; p = 0.002). <b>Conclusion:</b> Higher fatigue and lower limb functional limitations are significant predictors of future disability worsening in pwMS.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":\"13 3\",\"pages\":\"151-159\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/nmt-2022-0008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2022-0008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 3
摘要
患者报告结果(PROs)是多发性硬化症(pwMS)患者常规临床护理的重要指标。材料:从纽约州多发性硬化症协会中回顾性纳入干扰素-β-1a (IFN-β-1a)治疗的646例pwMS。收集入组时和3年随访时的临床和PRO数据。根据年龄、扩展残疾状态量表(EDSS)评分和疾病持续时间对病情稳定和残疾恶化的PwMS进行1:1匹配。根据试验标准确定残疾恶化。结果:未来EDSS恶化的PwMS有更高的基线和随访时间-25英尺步行(6.6 vs 5.5 s;9.1 vs 5.5 s;结论:重度疲劳和下肢功能受限是pwMS患者未来残疾恶化的重要预测因素。
Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users.
Introduction: Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). Materials: 646 pwMS treated with interferon-β-1a (IFN-β-1a) were retrospectively included from the New York State Multiple Sclerosis Consortium. Clinical and PRO data at enrollment and 3 year follow-up were collected. PwMS with stable disease and disability worsening were matched (1:1) based on age, Expanded Disability Status Scale (EDSS) scores and disease duration. Disability worsening was determined based on trial criteria. Results: PwMS with future EDSS worsening had higher baseline and follow-up timed-25-foot walk (6.6 vs 5.5 s; 9.1 vs 5.5 s; p < 0.001) when compared with stable pwMS. Worsening pwMS reported higher baseline difficulties in getting up (odds ratio [OR] = 2.4; p = 0.009), climbing stairs (OR = 1.6; p = 0.024) and standing (OR = 2.2; p < 0.001). Worsening pwMS reported greater lower limb limitations (OR = 2.3; p = 0.004) and fatigue (OR = 1.8; p = 0.002). Conclusion: Higher fatigue and lower limb functional limitations are significant predictors of future disability worsening in pwMS.